Levothyroxine Dosing: Morning, Night, or In Between? Levothyroxine Dosing: Morning, Night, or In Between?
Clinicians have traditionally told patients to take levothyroxine first thing in the morning, at least an hour before any food or drink. But does it really matter? Dr Leung looks at the evidence.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 22, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology Article Source Type: news

Merck Wins Lawsuit on Levothyroxine Saga in France Merck Wins Lawsuit on Levothyroxine Saga in France
Merck has prevailed in a first lawsuit that claimed that switching the formulation of levothyroxine in France caused patients harm. The company still faces further claims, however.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

PCOS Gene Variants; Testosterone and CAD; New Generic Levothyroxine
(MedPage Today) -- News and commentary from the endocrinology world (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - December 28, 2018 Category: OBGYN Source Type: news

TH Status During Levothyroxine Therapy in Hypothyroidism TH Status During Levothyroxine Therapy in Hypothyroidism
Does levothyroxine therapy effectively restore thyroid hormone signaling in patients with overt hypothyroidism?Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 27, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Euthyrox (Levothyroxine Sodium Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 19, 2018 Category: Drugs & Pharmacology Source Type: news

Lannett signs $50M distribution deal; stock up 10 percent
Lannett Co. Inc. entered into an agreement Monday with Amneal Pharmaceuticals Inc., under which Amneal will be the sole customer for Lannett's levothyroxine sodium tablets. The deal calls for Lannett, a Northeast Philadelphia generic drug company, to receive an upfront payment of $50 million. Other terms of the transaction were not disclosed. Lannett's stock opened up 10 percent at $5.88 per share Monday morning. The deal comes about three months after Lannett (N YSE: LCI) announced Jerome Stevens… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 12, 2018 Category: Pharmaceuticals Authors: John George Source Type: news

Lannett Enters Into Agreement With Amneal Pharmaceuticals For Levothyroxine
Lannett Locks in $50 Million of Gross Profit for 16-Week Period PHILADELPHIA, Nov. 12, 2018 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Amneal Pharmaceuticals... Biopharmaceuticals, Generics, Distribution Lannett Company, Amneal Pharmaceuticals, Levothyroxine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 12, 2018 Category: Pharmaceuticals Source Type: news

levothyroxine sodium (Synthroid, Levoxyl)
Title: levothyroxine sodium (Synthroid, Levoxyl)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 11/5/2018 12:00:00 AM (Source: MedicineNet Thyroid General)
Source: MedicineNet Thyroid General - November 5, 2018 Category: Endocrinology Source Type: news

The Love-Hate Relationship With Levothyroxine The Love-Hate Relationship With Levothyroxine
Levothyroxine, despite being the most prescribed drug in the United States, has many patients disenchanted and looking to T3 for symptom relief. How should clinicians approach the T4/T3 controversy?Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 25, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Article Source Type: news

Hypothyroidism drug improved with zinc
The new drug poly-zinc-liothyronine may perform better than liothyronine in patients with hypothyroidism who do not respond to levothyroxine, according to research published inThyroid.Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - October 15, 2018 Category: Endocrinology Source Type: news

Cholesterol Levels Remain High Despite T4 for Hypothyroidism Cholesterol Levels Remain High Despite T4 for Hypothyroidism
Despite their TSH levels being normalized with levothyroxine treatment, patients with hypothyroidism continue to show elevated cholesterol, a sign of continued thyroid signaling dysfunction.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 3, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Why Lannett's stock opened down 55 percent
Lannett Co. Inc. ’s stock opened down 55 percent, at $5.95 a share, Monday after the Northeast Philadelphia generic pharmaceutical maker announced a key distribution agreement was not being renewed. The distribution agreement with Jerome Stevens Pharmaceuticals (JSP), which will expire March 23, 2019, covers thre e JSP products: butalbital, aspirin, caffeine with codeine phosphate capsules; digoxin tablets; and levothyroxine sodium tablets. Tim Crew, Lannett’s CEO said the Steinlauf family, which… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 20, 2018 Category: American Health Authors: John George Source Type: news

Recall Alert: FDA Warning About Two Thyroid Medications
By Sandee LaMotte, CNN (CNN) — Certain batches of hypothyroid medications are being recalled by Westminster Pharmaceuticals after one of its Chinese suppliers failed a US Food and Drug Administration inspection. The medication in question contains a combination of levothyroxine, called LT4, and liothyronine, called LT3. Both are synthetic thyroid hormones used when a person’s thyroid gland is no longer functioning properly. “While we stand behind the quality of our product, we are taking the utmost precaution by recalling our Thyroid, USP Tablets only to the wholesale level due to a recent inspection by t...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 15, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Local TV Thyroid Source Type: news

Thyroid Tablets Recalled in US Because of Impurity Risk Thyroid Tablets Recalled in US Because of Impurity Risk
The combined levothyroxine (T4) and liothyronine (T3) thyroid tablets from Westminster Pharmaceuticals are being recalled to the wholesale level as a precaution because of a risk of adulteration.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 13, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration
Westminster Pharmaceuticals, LLC is voluntarily recalling all lots, within expiry, of Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg,& 120 mg to the wholesale level. These products are being recalled as a precaution because they were manufactured using active pharmaceutical ingredients that were sourced prior to the FDA ’s Import Alert of Sichuan Friendly Pharmaceutical Co., Ltd., which as a result of a 2017 inspection were found to have deficiencies with Current Good Manufacturing Practices (cGMP). Substandard cGMP practices could represent the possibility of risk being introduced into ...
Source: Food and Drug Administration - August 10, 2018 Category: Food Science Source Type: news